Investigators from the phase 3 ARAMIS trial reported a significant delay in PSA progression in patients with nonmetastatic CRPC receiving darolutamide.
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
Greater visceral and thigh subcutaneous fat are associated with higher risks of advanced and fatal prostate cancer (PCa), according to a new prospective study. In addition, visceral fat is associated with a higher risk of these outcomes among men with a lower body mass index (BMI). Investigators found no association between any adiposity measure and…
In a study of prostate cancer patients from North Carolina, only 15% received monitoring as recommended by the NCCN.
Addition of enzalutamide vs another nonsteroidal anti-androgen to standard of care is associated with significant improvement in overall survival among men with metastatic hormone-sensitive prostate cancer.
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
The proportion of men with metastatic prostate cancer who develop visceral metastases rose from 26% in 2009 to 40% in 2016, a study found.
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
Men with recurrent prostate cancer after radical prostatectomy had better 10-year metastasis-free survival when they received radiation therapy (RT) plus short-term hormone therapy rather than RT alone.